H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine Analyst Ratings
Optimistic Buy Rating for Mind Medicine's MM120 Amid Promising Phase 3 Progress and Strong Phase 2b Results
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Evercore Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $23
Mind Medicine Analyst Ratings
Evercore ISI Group Initiates Coverage On Mind Medicine With Outperform Rating, Announces Price Target of $23
Mind Medicine Price Target Announced at $20.00/Share by Chardan Capital
Mind Medicine Initiated at Buy by Chardan Capital
Mind Medicine Analyst Ratings
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
Mind Medicine (MNMD) Receives a Buy From Oppenheimer
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
Mind Medicine Analyst Ratings
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16